Bifidobacterium animalis subsp. lactis 420 mitigates the pathological impact of myocardial infarction in the mouse

Benef Microbes. 2017 Apr 26;8(2):257-269. doi: 10.3920/BM2016.0119. Epub 2017 Apr 14.

Abstract

There is a growing appreciation that our microbial environment in the gut plays a critical role in the maintenance of health and the pathogenesis of disease. Probiotic, beneficial gut microbes, administration can directly attenuate cardiac injury and post-myocardial infarction (MI) remodelling, yet the mechanisms of cardioprotection are unknown. We hypothesised that administration of Bifidobacterium animalis subsp. lactis 420 (B420), a probiotic with known anti-inflammatory properties, to mice will mitigate the pathological impact of MI, and that anti-inflammatory T regulatory (Treg) immune cells are necessary to impart protection against MI as a result of B420 administration. Wild-type male mice were administered B420, saline or Lactobacillus salivarius 33 (Ls-33) by gavage daily for 14 or 35 days, and underwent ischemia/reperfusion (I/R). Pretreatment with B420 for 10 or 28 days attenuated cardiac injury from I/R and reduced levels of inflammatory markers. Depletion of Treg cells by administration of anti-CD25 monoclonal antibodies eliminated B420-mediated cardio-protection. Further cytokine analysis revealed a shift from a pro-inflammatory to an anti-inflammatory environment in the probiotic treated post-MI hearts compared to controls. To summarise, B420 administration mitigates the pathological impact of MI. Next, we show that Treg immune cells are necessary to mediate B420-mediated protection against MI. Finally, we identify putative cellular, epigenetic and/or post-translational mechanisms of B420-mediated protection against MI.

Keywords: B. animalis ssp. lactis; cardiovascular disease; inflammation; probiotics; regulatory T cells.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Bifidobacterium animalis*
  • Cardiotonic Agents / therapeutic use*
  • Dietary Supplements / microbiology
  • Inflammation / immunology
  • Inflammation / therapy
  • Lactobacillus salivarius*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Myocardial Infarction / therapy*
  • Probiotics / therapeutic use*
  • T-Lymphocytes, Regulatory / immunology

Substances

  • Anti-Inflammatory Agents
  • Cardiotonic Agents